Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America

Abstract

Spontaneously-reported rates of adverse events (AEs) of intravenous (i. v.) iron products have not been compared since 2007. AEs in Europe (Eur) and North America (NA) have never been compared. New products have been marketed and many changes in prescribing habits have occurred since then, and the effect on AEs reporting is unclear. It was hypothesized that changing practices for i. v. iron products has caused changes in the rates of serious AEs and large differences exist between Eur and NA. Rates of AEs for three i. v. iron preparations (iron sucrose [IS], ferric gluconate [FG] and high and low MW iron dextran [HMWID, LMWID]) were compared by product and continent from January 1, 2003 to June 30, 2009 for selected countries in Eur and NA, using the Uppsala Monitoring Center’s database. Rates of total, anaphylaxis and other serious allergic AEs were calculated as number of AEs divided by i. v. iron sales standardized to 100 mg dose equivalents (DEq) of iron. Quarterly sales (millions of 100 mg DEq of iron) increased from the first quarter 2003 to the end of the second quarter of 2009 by 1% for FG, 16% for IS and 2% for ID. Total AEs for NA plus Eur were similar for FG and IS, but total AEs were 6- to 7-fold higher for ID. Rates of anaphylaxis were 6- to 11-fold higher in Eur plus NA combined for ID than for IS or FG. In NA, there were substantially higher reports for total, anaphylaxis and other serious allergic AEs with FG compared to IS, whereas the reverse was the case in Eur. Odds ratios (OR) showed higher risks of anaphylaxis with FG in NA vs. Eur (OR = 4.40, P < 0.0001) and lower risks with IS (OR = 0.24, P < 0.0001). Odds of anaphylaxis with LMWID in Eur vs. FG and IS were 42.08 and 16.92 (both P < 0.0001), respectively. In NA, odds of anaphylaxis with ID vs. FG and IS were 2.36 and 17.73 (both P < 0.0001), respectively.

Differences between NA and Eur may be related to varied treatment practices. ID had the highest rates of all types of AEs, and IS and FG had a continued trend for lowest rates of AEs.

Key words

Adverse events - Allergy - Anaphylaxis - Hypersensitivity - Intravenous iron

• References

• 1 Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S. A randomized controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005; 68: 2846-56
• 2 Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant. 1995; 10: 2070-6
• 3 Ahsan N. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study. J Am Soc Nephrol. 1998; 9: 664-8
• 4 Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K et al Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007; 13: 1545-53
• 5 Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC et al A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose randomized controlled trial. Am J Gastroenterol. 2007; 102: 1-11
• 6 Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency. Int J Gynaecol Obstet. 2008; 101 ((1)) 67-73 doi:101016/j.ijgo.2007. 10.009
• 7 Bayoumeu F, Subiran-Buisset C, Baka NE, Legagneur H, Monnie-Barbarino P, Laxenaire MC. Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. Am J Obstet Gynecol. 2002; 186: 518-22
• 8 Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009; 49: 2719-28
• 9 Love AL, Billett HH. Obesity, bariatric surgery, and iron deficiency: true, true, and related. Am J Hematol. 2007; 83: 403-9
• 10 Böiger AP, Bartlett FR, Penston HS, O’Leary J, Pollock N, Kaprielian R et al Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006; 48: 1225-7
• 11 Bastit A, Vandebroek A, Altintas S, Gaeda B, Pinter T, Suto TS et al Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008; 26: 1611-8
• 12 Rodgers GM, Becker PS, Bennett CL, Cella D, Chanan-Khan A, Chesney C et al National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: cancer- and chemotherapy-induced anemia. V.2.2010 [cited December 12, 2010]. Available from: http://www.nccn.org/index.asp
• 13 Drueke TB, Locatelli F, Clyne N, Eckhardt KU, Macdougall IC, Tsakiris D et al Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-84
• 14 Singh AK, Szczeck L, Tang KL, Barnhart H, Sapp S, Wolfson M et al Correction of anemia with epoetin alpha in chronic kidney disease. N Engl J Med. 2006; 355: 2085-98
• 15 Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckhadrt KU et al A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361: 2019-32
• 16 Heinze G, Kainz A, Horl WH, Oberbauer R. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study. BMJ. 2009; 339: b4018
• 17 Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayer JS. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA. 2010; 303: 857-64
• 18 Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant. 2005; 20: 1443-9
• 19 Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006; 21: 378-82
• 20 Wysowski DK, Swartz L, Borders-Hemphill BV, Goulding MR, Dormitzer C. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010; 85: 650-4
• 21 Weber JCP. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Rainslord KD, Velo EP. editors Advances in Inflammation Research. New York: Raven Press; 1984: 1-7
• 22 Horwitz RI, Feinstein AR. The problem of protopathic bias in case-control studies. Am J Med. 1980; 68: 255-8
• 23 Critchley J, Dundar Y. Adverse events associated with intravenous iron infusion (low molecular weight iron dextran and iron sucrose): a systematic review. Transf Alt Transf Med. 2007; 9: 8-36
• 24 U.S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2009
• 25 2009 Annual Report of the Dialysis Outcomes and Practice Patterns Study: Hemodialysis Data 1999–2008. Arbor Research Collaborative for Health, Ann Arbor, MI [cited December 12, 2010]. Available from: http://www.dopps.org/annualreportlindex.htm
• 26 Gonzales-Porras JR, Colado E, Conde MP, Lopez T, Nieto MJ, Corral M. An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty. Transfus Med. 2009; 19: 35-42
• 27 KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease, 2006 – [cited December 12, 2010]. Available from: http://www.kidney.org/professionals/KDOQI/guidelines_anemia/index.htm
• 28 KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target [cited December 12,2010]. Available from: http://www.kidney.org/professionals/KDOQI/guidelines_anemiaUP/index.htm
• 29 Locatelli F, Covic A, Eckhardt KU, Weicel A, Vanholder R. ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: position statement by the Anaemia Working Group of European Renal Best Practice (ERBP), 2008. Nephrol Dial Transplant. 2009; 24: 348-54
• 30 Canadian Society of Nephrology Clinical Practice Guidelines for the Management of Anemia Associated with Chronic Kidney Disease, 2008. Kidney Int. 2008; 74 (Suppl 110) S1-24
• 31 Caring for Australasians with Renal Impairment Clinical Practice Guidelines for Dialysis: Biochemical and Haematological Tests (Haemoglobin, 2008 and Iron, 2006) [cited December 12, 2010]. Available from: http://www.cari.org.au/dialysis_bht_published.php
• 32 Wikström B, Jacobson SH, Bragg-Gresham J, Eichleay M, Pisoni R, Port F. Dialysis Outcomes and Practice Patterns Study estimate of patient life-years attributable to modifiable haemodialysis practices in Sweden. Scand J Urol Nephrol. 2010; 44: 113-20
• 33 Mendelssohn DC, Pisoni RL, Arrington CJ, Yeates KE, Leblanc M, Deziel C et al A practice-related risk score: a DOPPS-derived aggregate quality index for haemodialysis facilities. Nephrol Dial Transplant. 2008; 23: 3227-33
• 34 Bailie GR, Mason NA, Tong L, Pisoni R, Locatelli F, Marshall MR et al Variation in parenteral iron use over time and between countries: the Dialysis Outcomes and Practice Patterns Study. Presented at XLVII ERA/EDTA Congress. Munich, Germany: June 2010. Abstract Sa-195
• 35 Singh AK. ESAs in dialysis patients: are you a hedgehog or a fox?. [editorial] J Am Soc Nephrol. 2010; 21: 543-6
• 36 Singh AK. Does TREAT give the boot to ESAs in the treatment of CKD anemia?. J Am Soc Nephrol. 2010; 21: 2-6
• 37 US Food and Drug Administration: FDA drug safety communication: ESAs – Procrit, Epogen and Aranesp [cited 2010 Sep 17]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatientsandProviders/ucm200297.htm
• 38 ESA APPRISE Oncology Program [cited 2010 Sep 17]. Available from: https://www.esa-apprise.com/ESAAppriseUI/ESAAppriseUI/terms.jsp
• 39 Toblli JE, Cao G, Oliveri L, Angerosa M. Differences between original intravenous iron sucrose and iron sucrose similar preparations. Arzneimittelforschung. 2009; 59: 176-90
• 40 Toblli JE, Cao G, Oliveri L, Angerosa M. Comparison of iron sucrose and iron sucrose similar substances on oxidative stress and inflammatory parameters in the rat. Presented at the annual meeting of the American Society of Nephrology, Denver, CO, November 2010, abstract # SA-PO2660.
• 41 Rottembourg J, Kadri A, Leonard E, Dansaert A, Lafuma A. Do two different intravenous iron sucrose preparations have the same efficacy?. Nephrol Dial Transplant. 2011; doi: 10.1093/ndt/gfr024